


Glycation modulates glutamatergic signalling and exacerbates Parkinson's disease-like phenotypes

Ana Chegão¹, Mariana Guarda¹, Bruno M. Alexandre^{2,3}, Liana Shvachiy⁴, Mariana Temido-Ferreira⁵, Inês Marques-Morgado⁵, Bárbara Fernandes Gomes¹, Rune Matthiesen¹, Luísa V. Lopes⁵, Pedro R. Florindo⁶, Ricardo Anjos-Gomes^{2,3}, Patrícia Gomes-Alves^{2,3}, Joana E. Coelho⁵, Tiago Fleming Outeiro^{4,7,8,9*}, Hugo Vicente Miranda^{1*}

¹CEOC, NOVA Medical School, NMS, Universidade NOVA de Lisboa, Lisboa, Portugal; ²Instituto de Tecnologia Química e Biológica António Xavier, Universidade Nova de Lisboa, Portugal; ³IET, Instituto de Biologia Experimental e Tecnológica, Portugal; ⁴Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Germany; ⁵Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Portugal; ⁶Instituto de Investigação do Medicamento (iMed.Ulisboa), Faculdade de Farmácia, Universidade de Lisboa, Portugal; ⁷Max Planck Institute for Experimental Medicine, Göttingen, Germany; ⁸Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom. Correspondence to hvmiranda@nms.unl.pt; touteir@gwdg.de.

Background


SYNUCLEINOPATHIES




HYPOTHESIS

Glycation-induced dysfunction of neuronal pathways might be an underlying molecular cause of synucleinopathies


Experimental design




MGO potentiates motor, cognitive, olfactory and colonic disturbances in Thy1-aSyn mice



MGO dysregulates glutamatergic signalling in the midbrain



MGO treatment induces neurodegeneration in Thy1-aSyn mice



TAKE-HOME MESSAGE

GLYCATION exacerbates motor, cognitive and olfactory deficits in Thy1-aSyn mice, that show accumulation of aSyn and AGEs and exacerbated glutamatergic signalling in the MIDBRAIN



MODEL

